Evidence map›Paper›PMID 38106886›Full record

ArticleFrontiers in public health2023

Using a web platform for equitable distribution of COVID-19 monoclonal antibodies: a case study in resource allocation.

Jonathon P Leider, Sarah Lim, Debra DeBruin, Alexandra T Waterman, Barbara Smith, Umesh Ghimire, Haley Huhtala, Zachary Zirnhelt, Ruth Lynfield, John L Hick

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jonathon P LeiderCenter for Public Health Systems, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, United States.
Sarah LimMinnesota Department of Health, Saint Paul, MN, United States.
Debra DeBruinCenter for Bioethics, University of Minnesota, Minneapolis, MN, United States.
Alexandra T WatermanMinnesota Department of Health, Saint Paul, MN, United States.
Barbara SmithHealth Sciences Technology, University of Minnesota, Minneapolis, MN, United States.
Umesh GhimireCenter for Public Health Systems, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, United States.
Haley HuhtalaHealth Sciences Technology, University of Minnesota, Minneapolis, MN, United States.
Zachary ZirnheltMinnesota Department of Health, Saint Paul, MN, United States.
Ruth LynfieldMinnesota Department of Health, Saint Paul, MN, United States.
John L HickHennepin Healthcare, Minneapolis, MN, United States.
University of Minnesota · USMinnesota Department of Health · USHennepin Healthcare Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While medical countermeasures in COVID-19 have largely focused on vaccinations, monoclonal antibodies (mAbs) were early outpatient treatment options for COVID-positive patients. In Minnesota, a centralized access platform was developed to offer access to mAbs that linked over 31,000 patients to care during its operation. The website allowed patients, their representative, or providers to screen the patient for mAbs against Emergency Use Authorization (EUA) criteria and connect them with a treatment site if provisionally eligible. A validated clinical risk scoring system was used to prioritize patients during times of scarcity. Both an ethics and a clinical subject matter expert group advised the Minnesota Department of Health on equitable approaches to distribution across a range of situations as the pandemic evolved. This case study outlines the implementation of this online platform and clinical outcomes of its users. We assess the impact of referral for mAbs on hospitalizations and death during a period of scarcity, finding in particular that vaccination conferred a substantially larger protection against hospitalization than a referral for mAbs, but among unvaccinated users that did

Indexed as

COVID-19HumansPandemicsResource AllocationSARS-CoV-2case studyCOVID-19 responsecrisis standards of careequitable allocation of resourcesmonoclonal antibodypublic health preparednessscarce resource allocation

Identifiers

PMID38106886
PMCPMC10722896
OpenAlexW4389097565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.